BP
PRAX icon

Ballentine Partners’s Praxis Precision Medicines PRAX Stock Holding History

Ballentine Partners’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,911
Closed -$451K – 877
2024
Q2 		$451K Buy
+10,911
New +$516K 0.01% 428

Other funds holding PRAX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Ballentine Partners's PRAX Position: Q3 2024 in Review

Ballentine Partners sold out of Praxis Precision Medicines (PRAX) in Q3 2024, closing a stake of 10,911 shares — an estimated $451K sold.

Ballentine Partners first reported a position in PRAX in Q2 2024 and held it in 1 quarter. The position peaked at $451K in Q2 2024. 134 funds tracked by Wall St. Rank hold PRAX as of Q3 2024.

  • Ballentine Partners reported no remaining Praxis Precision Medicines position as of Q3 2024 after selling out during the quarter.
  • Ballentine Partners sold 10,911 Praxis Precision Medicines shares in Q3 2024, an estimated $451K.
  • Ballentine Partners first reported a position in Praxis Precision Medicines in Q2 2024 and held it in 1 quarter.
  • Ballentine Partners's Praxis Precision Medicines position peaked at $451K in Q2 2024.
  • 134 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q3 2024.

Based on Ballentine Partners's 13F filing for Q3 2024, filed 23 Oct 2024.